A midstage Japanese study involving 34 patients with multiple myeloma, who were administered 100-mg maintenance doses of thalidomide daily, found that the dosage was safe and effective in hindering disease progression for longer than 36 months. The study's findings were reported in the International Journal of Hematology.
100-mg daily dose of thalidomide in myeloma delays disease progression
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.